A Comparison of Intensive Sequential Chemotherapy using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women with >= 4 Involved Axillary Lymph Nodes, Phase III, Intergroup.
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials
High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials [PMID21768471]
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623 [PMID17404368]
SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (ACHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes.